Drug intelligence / Profile preview

ATR-339

Development stage: Preclinical
Lead developer: Atrogi
Modality: Small Molecules

Overview

ATR-339 is a preclinical-stage small molecule drug candidate developed by Atrogi. It is designed to target the β₂-adrenergic receptor to restore metabolic function while simultaneously preserving muscle mass. The drug is being developed for the treatment of obesity and muscle-wasting conditions. ATR-339 belongs to a novel class of β₂-adrenergic receptor modulators that aim to address metabolic dysfunction by improving muscular insulin sensitivity and glucose uptake, potentially avoiding the typical side effects associated with traditional β₂-agonists.

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on ATR-339.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATR-339.

Explore the full profile